TrialBMC cancer2016

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma.

Marc-Andrea Baertsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.